Literature DB >> 10626144

Monoclonal gammopathies of undetermined significance.

R A Kyle1, S V Rajkumar.   

Abstract

Monoclonal gammopathy of undetermined significance is characterized by a serum M-protein level less than 3 g/dL, fewer than 10% plasma cells in the bone marrow, and no or only small amounts of M-protein in the urine; by the absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency; and most importantly, by the stability of the M-protein and by the failure of other abnormalities to develop. Monoclonal gammopathy of undetermined significance is found in approximately 3% of persons older than 70 years and in 1% of those older than 50 years. Approximately one fourth of patients develop MM, AL, WM, or a similar malignant lymphoproliferative disorder during long-term follow-up. In a series of 241 patients at the Mayo Clinic, the actuarial rate of development of serious disease was 16% at 10 years and 40% at 25 years. The median interval from recognition of the M-protein to the diagnosis of MM was 10 years (range, 2-29 years). The plasma cell labeling index and the presence of circulating plasma cells in the peripheral blood suggest active disease. There are no findings at the time of recognition of MGUS that distinguish patients who will remain stable from those in whom a malignant plasma cell proliferative disorder will develop. Therefore, one must perform serial measurements of the M-protein and periodically evaluate the clinical and laboratory features.

Entities:  

Mesh:

Year:  1999        PMID: 10626144     DOI: 10.1016/s0889-8588(05)70120-9

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  14 in total

1.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Ashraf H Ibrahim; Elizabet Dachs Cabanas; Rebecca K M Protheroe; David M Stockley; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

2.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

3.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

4.  The role of serum protein electrophoresis in the detection of multiple myeloma: an experience of a corporate hospital.

Authors:  Sunita Tripathy
Journal:  J Clin Diagn Res       Date:  2012-11

5.  Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Rebecca K M Protheroe; David M Stockley; Alastair G Smith; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

6.  IgAλ monoclonal gammopathy of undetermined significance (MGUS) associated with primary selective IgM deficiency.

Authors:  Sudhir Gupta; Sudhanshu Agrawal
Journal:  Am J Clin Exp Immunol       Date:  2019-08-15

Review 7.  The effect of age on the B-cell repertoire.

Authors:  M E Weksler; P Szabo
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.542

8.  Paraproteinemic Neuropathy.

Authors:  Matthew P. Wicklund; John T. Kissel
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

9.  Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies.

Authors:  R C Tschumper; A Dispenzieri; R S Abraham; K J Henderson; D F Jelinek
Journal:  Blood Cancer J       Date:  2013-04-19       Impact factor: 11.037

10.  A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.

Authors:  Madhav V Dhodapkar; Matthew D Geller; David H Chang; Kanako Shimizu; Shin-Ichiro Fujii; Kavita M Dhodapkar; Joseph Krasovsky
Journal:  J Exp Med       Date:  2003-06-09       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.